• Increase font size
  • Default font size
  • Decrease font size

Small Diagnostics Company Aims To Change Lab Field Testing (OTC:BMGP)

Print E-mail
By M.E.Garza   
Wednesday, 14 October 2009 03:00
Diagnostics, the technologies and tools used to identify diseases and conditions in patients make up the second-largest portion of the biotechnology industry.  A new technology, originally developed with funding from the Department of Homeland Security, allows laboratories to perform far more tests in the same amount of time it takes to do a single test and is designed to detect the actual virus and viral load in any body fluid.


BMGP Receives a Financing Commitment 
to Speed Development of Malaria Testing

BMGP Enters into Agreement
with One of China's Largest Dairies


BMGP Appoints Rothschild
as Special Adviser to Board


Biomagnetics Diagnostics Corp. (OTC:BMGP) is a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing. 

Several key developments have put this company on our radar screen including the fact that there is significant demand throughout the world for advanced field deployable testing technologies.

The company has made it one of their goals to provide innovative products to meet this demand and to deploy their testing equipment and technologies in the field as well as in the clinical setting for a wide variety of pathogens.

Joe Noel, who introduced many investors to BioElectronics Corporation, tells us about this intriguing penny stock play within the diagnostics space.

A special, in-depth audio interview can be heard below (click on the player under the image):





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 8 hours ago Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data: Below i... http://t.co/IbLYNqgb
about 17 hours ago Shares of $IDIX drop slightly after compelling new data from rival Gilead ($GILD) puts prospects for IDIX's hepatitis C drug in question.
about 1 day ago Medgenics has Key to Protein Therapy Market: Medgenics (NASDAQ: MDGN) has what I believe to be the most disrupti... http://t.co/c3IBIWYR
about 1 day ago Stocks Vacillate To Mixed Finish; Some Leaders Rally http://t.co/dtOQTRgh
about 1 day ago Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR: Belo... http://t.co/a7IlIvbS
about 1 day ago Athersys $ATHX gets grant to study traumatic brain injury http://t.co/mnZTsxXx
about 1 day ago Watching: San Antonio patients help test new 'spray-on skin' for burns http://t.co/fzKA9B23
about 1 day ago OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012: During the past few sessi... http://t.co/fKOMc1TM

navigation

Free Phone Trade Alerts